{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:33:19Z","timestamp":1784543599049,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"the Ministry of Education, Culture, Sports, Science and Technology in Japan","doi-asserted-by":"crossref","award":["Kiban-C #20K08561"],"award-info":[{"award-number":["Kiban-C #20K08561"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"the Ministry of Education, Culture, Sports, Science and Technology in Japan","doi-asserted-by":"crossref","award":["the Kanto Academic Alliance for Fostering Cancer Professionals"],"award-info":[{"award-number":["the Kanto Academic Alliance for Fostering Cancer Professionals"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Salivary gland-type cancers (SGTCs) are histologically heterogeneous and can affect organs other than the salivary glands. Some tumors outside the salivary glands are diagnosed on their unique histological characteristics. Comprehensive cross-organ studies on SGTCs are limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analyzed the data of patients with salivary duct carcinoma (SDC), adenoid cystic carcinoma (AdCC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), acinic cell carcinoma (AcCC), and polymorphous adenocarcinoma (PAC) who visited our institution between 2009 and 2019. The primary tumor sites were classified into four categories; major salivary glands, head\/neck (H\/N) excluding (exc) major salivary glands (MSG) regions, broncho-pulmonary regions, and \u201cothers\u201d. H\/N exc MSG was further divided into three subcategories, nasal\/paranasal sinus, oral and pharynx\/larynx.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 173 patients with SGTCs, with SDC, AdCC, MEC, EMC, AcCC, and PAC accounting for 20%, 42%, 27%, 3%, 8%, and 1% of the cases, respectively. The most frequent primary site was the major salivary glands (64%), followed by H\/N exc MSG regions (27%), broncho-pulmonary regions, and \u201cothers\u201d, thus non-salivary gland origins accounted for 9% of all cases. Patients with SDC, MEC, AcCC, or SGTC of the major salivary glands and broncho-pulmonary regions were more frequently treated by surgery. The overall survival time of the patients with MEC was significantly better than that of patients with SDC or EMC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This cross-organ study highlights the clinical significance of SGTCs, underscoring the need for developing novel therapies for this rare disease entity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-024-02505-3","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T07:02:11Z","timestamp":1710572531000},"page":"755-763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Salivary gland-type cancers: cross-organ demographics of a rare cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Aika","family":"Tanzawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoyuki","family":"Hanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-7476","authenticated-orcid":false,"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"issue":"5","key":"2505_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1034\/j.1601-0825.2002.02870.x","volume":"8","author":"PM Speight","year":"2002","unstructured":"Speight PM, Barrett AW (2002) Salivary gland tumours. Oral Dis 8(5):229\u2013240. https:\/\/doi.org\/10.1034\/j.1601-0825.2002.02870.x","journal-title":"Oral Dis"},{"key":"2505_CR2","unstructured":"Cancer Information Service, National Cancer Center, Japan. Annual Survival Report of Hospital-Based Cancer Registries (2023) https:\/\/jhcr-cs.ganjoho.jp\/hbcrtables\/wpSiteSearch.aspx?UnitType=2. Accessed 15 Nov 2023"},{"issue":"7","key":"2505_CR3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1080\/003655402_000028047","volume":"122","author":"MS Brandwein","year":"2002","unstructured":"Brandwein MS, Ferlito A, Bradley PJ et al (2002) Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta Otolaryngol 122(7):758\u2013764","journal-title":"Acta Otolaryngol"},{"issue":"3","key":"2505_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/hed.2890080309","volume":"8","author":"RH Spiro","year":"1986","unstructured":"Spiro RH (1986) Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8(3):177\u2013184. https:\/\/doi.org\/10.1002\/hed.2890080309","journal-title":"Head Neck Surg"},{"issue":"1","key":"2505_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/path.1711460106","volume":"146","author":"JW Eveson","year":"1985","unstructured":"Eveson JW, Cawson RA (1985) Salivary gland tumours. a review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol 146(1):51\u201358. https:\/\/doi.org\/10.1002\/path.1711460106","journal-title":"J Pathol"},{"key":"2505_CR6","unstructured":"WHO Classification of salivary gland tumors (2017) 4th edn. International Agency for Reserch on Cancer"},{"issue":"7","key":"2505_CR7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.oraloncology.2007.08.018","volume":"44","author":"C Copelli","year":"2008","unstructured":"Copelli C, Bianchi B, Ferrari S et al (2008) Malignant tumors of intraoral minor salivary glands. Oral Oncol 44(7):658\u2013663. https:\/\/doi.org\/10.1016\/j.oraloncology.2007.08.018","journal-title":"Oral Oncol"},{"issue":"4","key":"2505_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1053\/j.semdp.2003.09.001","volume":"20","author":"AK Bennett","year":"2003","unstructured":"Bennett AK, Mills SE, Wick MR (2003) Salivary-type neoplasms of the breast and lung. Semin Diagn Pathol 20(4):279\u2013304. https:\/\/doi.org\/10.1053\/j.semdp.2003.09.001","journal-title":"Semin Diagn Pathol"},{"key":"2505_CR9","unstructured":"Salivary gland-type tumours (2021) In: Thoracic tumors: WHO classification of tumours, vol 5. 5th edn. International Agency for Reserch on Cancer, pp 115\u2013126"},{"key":"2505_CR10","unstructured":"Rare and salivary gland-type tumours (2019) In: Breast tumors: WHO classification of tumours, vol 2. 5th edn. International Agency for Reserch on Cancer, pp 139\u2013154"},{"issue":"11","key":"2505_CR11","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.5858\/arpa.2021-0093-RA","volume":"145","author":"M Wang","year":"2021","unstructured":"Wang M, Gilani S, Xu H et al (2021) Salivary gland-type tumors of the lung: a distinct group of uncommon lung tumors. Arch Pathol Lab Med 145(11):1379\u20131386. https:\/\/doi.org\/10.5858\/arpa.2021-0093-RA","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2505_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/030089160909500406","volume":"95","author":"M Nagliati","year":"2009","unstructured":"Nagliati M, Bolner A, Vanoni V et al (2009) Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori 95(4):442\u2013448. https:\/\/doi.org\/10.1177\/030089160909500406","journal-title":"Tumori"},{"issue":"7","key":"2505_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.joms.2005.03.006","volume":"63","author":"RB Bell","year":"2005","unstructured":"Bell RB, Dierks EJ, Homer L et al (2005) Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 63(7):917\u2013928. https:\/\/doi.org\/10.1016\/j.joms.2005.03.006","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"2505_CR14","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.athoracsur.2018.01.055","volume":"105","author":"BJ Resio","year":"2018","unstructured":"Resio BJ, Chiu AS, Hoag J et al (2018) Primary salivary type lung cancers in the national cancer database. Ann Thorac Surg 105(6):1633\u20131639. https:\/\/doi.org\/10.1016\/j.athoracsur.2018.01.055","journal-title":"Ann Thorac Surg"},{"key":"2505_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.oraloncology.2017.09.008","volume":"74","author":"NC Schmitt","year":"2017","unstructured":"Schmitt NC, Kang H, Sharma A (2017) Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol 74:40\u201348. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.09.008","journal-title":"Oral Oncol"},{"key":"2505_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac080","author":"X Le","year":"2022","unstructured":"Le X, Baik C, Bauman J et al (2022) Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyac080","journal-title":"Oncologist"},{"key":"2505_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad154","author":"S Takamori","year":"2023","unstructured":"Takamori S, Yatabe Y, Osoegawa A et al (2023) Rare but clinically important salivary gland-type tumor of the lung: a review. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyad154","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"2505_CR18","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1007\/s00405-023-08110-w","volume":"280","author":"M \u017burek","year":"2023","unstructured":"\u017burek M, Fus \u0141, Niemczyk K et al (2023) Salivary gland pathologies: evolution in classification and association with unique genetic alterations. Eur Arch Otorhinolaryngol 280(11):4739\u20134750. https:\/\/doi.org\/10.1007\/s00405-023-08110-w","journal-title":"Eur Arch Otorhinolaryngol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02505-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T08:23:03Z","timestamp":1716798183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02505-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02505-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In relation to conflict of interests pertaining to the present study, Izumi Ohno has received lecture fees from AstraZeneca, Daiichi-Sankyo, Novartis, Chugai pharmaceutical co., Ono pharmaceutical co., Bristol Meyers Squib, and Merck Sharp and Dohme. Toyoyuki Hanazawa has received lecture fees from Ono pharmaceutical co., and Merck Sharp and Dohme. Yuichi Takiguchi has received lecture fees from AstraZeneca, Daiichi-Sankyo, Novartis, Chugai pharmaceutical co., Bristol Meyers Squib, Pfizer, and Merck Sharp and Dohme, and research funds from AstraZeneca, Chugai pharmaceutical co., Ono pharmaceutical co., Pfizer, and Merck Sharp and Dohme. The other authors have no conflict of interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed and approved by the institutional review board of Graduate School of Medicine, Chiba University (approval number M10019). The need to obtain patient written informed consent for participation in this study was waived and an opt-out method for obtaining consent was applied based on indication from the IRB, because of the retrospective nature of the study and absence of any intervention.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}